bluebird bio
NEWS
The cancers were diagnosed 19 to 92 months after Skysona treatment.
Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.
Bluebird has just two quarters until it’s out of cash. Executives are looking for financing to extend that runway to a projected breakeven point before the end of 2025, with analysts worried they won’t make it.
J&J beat expectations this week to launch the Q3 earnings season; a study about children treated with bluebird bio’s Skysona comes at a bad time for the company; Sen. Warren calls for scrutiny of Novo’s purchase of Catalent; and other news.
To say that 2seventy bio’s short two years of existence have been dramatic is an understatement. CEO Chip Baird told BioSpace transparency and a committed staff have kept the biotech going through thick and thin.
About a month after reporting it’s had a tough time starting enough patients on its treatments, bluebird bio announced it will lay off about 25% of its employees, over half of whom work in R&D.
Infusions of Vertex and CRISPR Therapeutics’ Casgevy and bluebird bio’s Lyfgenia have begun; Moderna targets 10 approvals through 2027; more oral obesity drug data; the latest from ESMO and more.
Last month, Vertex said sickle cell patients had not yet received infusions of its gene therapy Casgevy. That’s now changed, as the company races with bluebird bio’s Lyfgenia.
Likely to miss its initiation target, bluebird bio has renegotiated the loan deals of its agreement with Hercules Capital, giving it until June 30 next year—at the latest.
JOBS
IN THE PRESS
bluebird bio, Inc. (Nasdaq: BLUE) today announced that O. James Sterling, has been appointed chief financial officer (CFO), effective June 10, 2024.
bluebird bio, Inc. announced that it has completed the first commercial cell collection for LYFGENIA, a one-time gene therapy for the treatment of sickle cell disease in patients with a history of vaso-occlusive events.
bluebird bio, Inc. announced that it will host a conference call to discuss first quarter 2024 results and business updates on May 9, at 8:00 a.m. ET.